GGrantIndex
Sort

64,565 grants matching drug discovery

Regulation of resistance to CDK4/6 inhibitor in breast cancer

$633,959
Wenge Zhu · George Washington University · R01 · FY2025 · CA

The multiple antibiotic resistance (Mar) regulon

$633,945
Stuart B. Levy · Tufts University Boston · R01 · FY2012 · AI

Research Core

$633,838
W Kelley Thomas · University Of New Hampshire · P20 · FY2017 · GM

Project 1: Systematic discovery of cell-intrinsic mechanisms of cancer drug resistance

$633,787
Scott R Manalis · Massachusetts Institute Of Technology · U54 · FY2019 · CA

Mechanisms of FGF Receptor Regulation and Signaling

$633,765
Moosa Mohammadi · New York University School Of Medicine · R01 · FY2011 · DE

New Quantitative Neuroimaging Metrics of Structural and Functional Connectivity of the Locus Coeruleus as a Novel Biomarker of Alzheimer's Disease Pathogenesis and Progression

$633,753
Lawrence R. Frank · University Of California, San Diego · R01 · FY2019 · AG

The molecular genetic analysis of human obesity

$633,735
Rudolph L Leibel · Columbia University Health Sciences · R01 · FY2018 · DK

Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP

$633,691
Peter Alexander Ljubenkov · University Of California, San Francisco · R01 · FY2024 · AG

Immunology Team Contributions to the LSB

$633,676
Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

Rational Design of Antibiotics Targeted at the Ribosome

$633,600
Anadys Pharmaceuticals, Inc. · R44 · FY2005 · AI

Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity

$633,596
Aarti Asnani · Beth Israel Deaconess Medical Center · R01 · FY2024 · HL

Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB)

$633,557
Louise Sumner · Gryphon Scientific, Llc · N01 · FY2020 · AI

Does neurotransmitter plasticity of para-serotonergic neurons augment autoresuscitation following perinatal stress and buffer SIDS risk?

$633,400
Susan M Dymecki · Harvard Medical School · R01 · FY2024 · HD

Machine learning drives translational research from drug interactions to pharmacogenetics

$633,396
Lang Li · Ohio State University · R01 · FY2023 · LM

The Impact of Pharmaceutical Industry Messaging on the Opioid Crisis among U.S. Military Veterans

$633,328
Christopher Keith Haddock · Ndri-Usa, Inc. · R01 · FY2025 · DA

Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment

$633,319
Todd D Gould · University Of Maryland Baltimore · R01 · FY2022 · MH

A NOVEL MICROFLUIDIC DEVICE FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHIC

$633,309
Balabhaskar Prabhakarpandian · Cfd Research Corporation · R44 · FY2012 · CA

Alzhelmer's Disease Drug Development Program

$633,176
Amos B Smith · University Of Pennsylvania · U01 · FY2008 · AG

Genetic Analysis of Toxinogenesis in Vibrio Cholerae

$633,171
John J Mekalanos · Harvard Medical School · R01 · FY2009 · AI

Cannabinoid CB2 Receptor Structure and Allosteric Modulators

$633,135
Xiang-Qun Xie · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · DA

Cannabinoid CB2 Receptor Structure and Allosteric Modulators

$633,135
Xiang-Qun Xie · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · DA

Cannabinoid CB2 Receptor Structure and Allosteric Modulators

$633,135
Xiang-Qun Xie · University Of Pittsburgh At Pittsburgh · U01 · FY2025 · DA

Developing Autophagy-Targeting Chimeras and Optimizing Cell Penetration of Large-Molecule Therapeutics

$633,124
Joshua A Kritzer · Tufts University Medford · R35 · FY2024 · GM

Interference with Androgen Receptor and Its Ligands

$633,005
James L Mohler · Univ Of North Carolina Chapel Hill · P01 · FY2010 · CA

Medicinal Chemistry

$633,001
Craig Lindsley · Vanderbilt University · U01 · FY2014 · MH